None listed
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: MS patients: disease type should be primary progressive and EDSS should be 0-6.5 Both patients and healthy controls should have an age between 18-60 years of age
Exclusion criteria
Exclusion criteria: Immunomodulatory medication Claustrophobia or other contraindications to MRI Neurological or psychiatric disease or history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To improve the sensitivity of surrogate markers for neuroaxonal damage for clinical trials by combining MR measures longitudinally. To assess if any baseline measures of atrophy, NAA/Cr, MTI or DTI predicts a subgroup of patients who subsequently have greatest rates of atrophy. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess whether potential serum and urine biomarkers of neurodegeneration may have added value. To produce data for powering neuroprotective studies for all of the different combinations of MR and biological fluid markers. This would allow selection of measures in the future depending on the study requirements. To assess reproducibility and reliability of the data between centers. | — |
Countries
Netherlands
Outcome results
None listed